Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients.

Diya Hasan,Iyad Natsheh,Amid Abdelnour,Yazan Ismail,Mohanad Ode,George J Burghel,Safaa Al-Zeidaneen,Ahmad Al Tibi

doi:10.31557/apjcp.2021.22.10.3355

Abstract

Objective:This study aimed to investigate level fluctuations of serum biomarkers that are associated with cardiotoxicity risk, such as high-sensitivity C-reactive protein (hs-CRP) and apolipoprotein-B (Apo-B) in response to chemotherapy treatment for breast cancer. Method:The serum levels of hs-CRP and Apo-B were evaluated in 56 breast cancer patients with main inclusion criteria: HER2 negative and who received adjuvant chemotherapy AC [A: Adriamycin, C: Cyclophosphamide] or AC→T [A: Adriamycin, C: Cyclophosphamide, T: Taxane] regimes at early II (n = 26) and late IV (n = 30) clinical stages by using particle enhanced turbidimetric assay. Results:The results of this study suggest that a high level of pre-treatment hs-CRP is a good prognostic marker in comparison to Apo-B. Moreover, the AC-T chemotherapy regime treatment in both early and late stages exhibited a significantly higher level of hs-CRP compared to that in the AC regime. Hs-CRP was significantly elevated in the early stage in comparison to the late stage among cancer patients, meanwhile Apo-B behaved inversely. Furthermore, the results showed that hs-CRP levels were significantly higher in late-stage cancer patients compared with those in early-stage in both chemotherapy regimens groups. On the other hand, Apo-B showed no significant differences. Conclusion:Monitoring hs-CRP level changes in comparison to Apo-B can be used to assist the side effect risk difference among different chemotherapy regimens, and staging reflecting a positive correlation between them more notable in the late stage.

Highlights

Breast cancer is the most common cancer that affects women in Jordan
This study aimed to investigate level fluctuations of serum biomarkers that are associated with cardiotoxicity risk, such as high-sensitivity C-reactive protein and apolipoprotein-B (Apo-B) in response to chemotherapy treatment for breast cancer
It was found that both high-sensitivity C-reactive protein (hs-C-reactive protein (CRP)) levels and Apo-B markers were significantly elevated in breast cancer patients at the time of diagnosis, in comparison with healthy controls with a preference for hs-CRP over Apo-B

Summary

Introduction

Breast cancer is the most common cancer that affects women in Jordan. It has a high mortality rate, as it commonly occurs after lung and colorectal cancers (Abdel-Razeq et al, 2020). Chemotherapy regimens usually consist of a combination of drugs that are given in a number of cycles at a set period of time, depending on the effectiveness of clinical trials for a specific regimen. There are many types of chemotherapy used to treat breast cancer, among them are alkylating agents such as Cyclophosphamide (Cytoxan), anthracycline antibiotics, and antineoplastics such as Doxorubicin hydrochloride (Adriamycin), and antimicrotubule and Taxane derivatives such as paclitaxel (Taxol) and docetaxel (Taxotere). Chemotherapy regimen could be given as AC [A: Adriamycin, C: Cyclophosphamide]

Methods

Results

Conclusion